Ezogabine for the adjunctive treatment of partial onset seizures in adults with epilepsy

Michele A. Faulkner

Research output: Contribution to journalReview articlepeer-review


Partial seizures are frequently resistant to pharmacologic treatment. There are a plethora of medications currently approved for use in partial epilepsy. However, despite the large number of medications available, seizure control often remains elusive. A new medication with a unique mechanism of action has recently been approved for the adjunctive treatment of partial seizures in adults. Ezogabine (retigabine) exerts its actions at the level of voltage-gated potassium channels. In clinical trials it has demonstrated efficacy similar to that of other agents approved for resistant partial epilepsy. Adverse events tend to be central nervous system related. However, significant urinary retention has been noted in some persons exposed to the drug. A Risk Evaluation and Mitigation Strategy is being implemented to minimize urinary adverse events. Ezogabine represents an important addition to the partial epilepsy medication arsenal.

Original languageEnglish (US)
Pages (from-to)441-448
Number of pages8
JournalClinical Medicine Insights: Therapeutics
StatePublished - 2011

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science


Dive into the research topics of 'Ezogabine for the adjunctive treatment of partial onset seizures in adults with epilepsy'. Together they form a unique fingerprint.

Cite this